Demographic and clinical characteristics of study patients. Values are expressed as mean (SD) unless otherwise indicated.
| Characteristic | RA | OA | FM |
|---|---|---|---|
| Clinic data | |||
| Subjects, n | 2096 | 1440 | 1073 |
| Age, yrs | 59.2 (14.0) | 63.4 (12.4) | 49.2 (12.9) |
| Sex, % male | 26.5 | 24.7 | 5.8 |
| Median disease duration, yrs | 10.8 (10.0) | 8.0 (10.3) | 8.0 (10.5) |
| Tender joint count, 0–28 | 4.9 (6.4) | ||
| Swollen joint count, 0–28 | 3.7 (4.8) | ||
| ESR, mm/h | 25.6 (23.2) | ||
| Global severity, 0–10 | 4.2 (2.7) | 4.3 (2.6) | 6.2 (2.4) |
| DAS28 | 3.7 (1.5) | ||
| Fatigue, 0–10 | 4.9 (2.9) | 4.8 (2.9) | 7.6 (2.2) |
| MD global inflammation activity, 0–10 | 3.4 (2.3) | 3.5 (1.9) | 4.1 (2.0) |
| Pain | 4.5 (2.8) | 5.1 (2.6) | 6.7 (2.3) |
| HAQ2, 0–3 | 1.1 (0.7) | 0.9 (0.6) | 1.3 (0.6) |
| Survey data | |||
| Subjects, n | 14,607 | 3173 | 2487 |
| Age, yrs | 60.7 (13.8) | 67.7 (11.7) | 55.4 (12.5) |
| Sex, % male | 22.7 | 20.5 | 4.7 |
| Median disease duration, yrs | 12.6 (12.5) | 18.3 (13.7) | 13.3 (11.3) |
| Global severity, 0–10 | 3.6 (2.5) | 3.6 (2.5) | 4.9 (2.5) |
| Fatigue, 0–10 | 4.5 (3.0) | 4.4 (2.9) | 6.3 (2.7) |
| Pain, 0–10 | 3.9 (2.8) | 4.2 (2.7) | 5.9 (2.6) |
| HAQ2, 0–3 | 1.0 (0.7) | 1.0 (0.6) | 1.2 (0.6) |
ESR: erythrocyte sedimentation rate; DAS28: Disease Activity Score-28; HAQ2: Health Assessment Questionnaire II.